Top 20 Shareholders October 2022
Top_Holders_Report OCT
PharmAust doses first patient with MPL in motor neurone disease trial
PharmAust doses first patient with MPL in motor neurone disease trial (External link)
PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease
PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease (External link)
PharmAust (ASX:PAA) doses first patient in MND trial
PharmAust (ASX:PAA) doses first patient in MND trial (External ink)
First Patient Dosed in MND Phase 1/2 Trial
First Patient Dosed in MND Phase 1-2 Trial
Top 20 Shareholders
Top_Holders_Report (1)
Notice of Annual General Meeting 2022
Notice of AGM 2022
PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin
PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin (External Link)
Update on PharmAust Canine Cancer Trials
Update on PharmAust Canine Cancer Trials
PharmAust’s MPL trials show doubled life expectancy for dogs with cancer
PharmAust’s MPL trials show doubled life expectancy for dogs with cancer (External Link)